0IJO Stock Chart & Stats
$56.12
-$0.56(-1.00%)
At close: 4:00 PM EDT
$56.12
-$0.56(-1.00%)
Day’s Range― - ―
52-Week Range$33.81 - $57.49
Previous CloseN/A
Volume3.00
Average Volume (3M)2.21K
Market Cap
$12.72B
Enterprise Value$13.83K
Total Cash (Recent Filing)$839.38M
Total Debt (Recent Filing)$165.93M
Price to Earnings (P/E)15.3
Beta0.86
Next Earnings
Nov 03, 2026EPS Estimate
0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.29
Shares Outstanding247,781,700
10 Day Avg. Volume1,091
30 Day Avg. Volume2,207
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)5.48
Price to Sales (P/S)5.10
P/FCF Ratio14.02
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$51.75Price Target Upside-7.79% Downside
Rating ConsensusHold
Number of Analyst Covering14
EPS Forecast (FY)3.5
Revenue Forecast (FY)$2.55B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationTTM operating and free cash flow near $1.44B each indicates durable cash generation and high cash conversion. That level of FCF funds ongoing R&D, supports the sizable buyback program and potential M&A or partnerships, reducing dependence on external financing over coming quarters.
High And Improving ProfitabilitySustained TTM net margin (~35%) and EBITDA margin (~42%) reflect strong operating leverage and pricing power for core products. Elevated margins create durable internal funding for pipeline advancement and shareholder returns and improve resilience to cyclical revenue swings typical in biotech.
Leading Franchise And Advancing Late‑stage PipelineMarket leadership with CABOMETYX and an advancing zanzalintinib program (NDA/PDUFA and several pivotal trials) provide a durable growth runway beyond the current franchise. A successful zanza approval and subsequent readouts could diversify revenue and extend competitive positioning over the medium term.
Bears Say
Lowered Full‑year Revenue GuidanceA $50M downward adjustment and a narrowed revenue range reduce near‑term topline visibility and signal a slower commercial ramp in NET. This complicates multi‑quarter planning and could limit optionality for incremental R&D spend or dealmaking if patient kinetics remain slower than modeled.
Rising Gross‑to‑net PressureAn increase in expected gross‑to‑net to 30–31% structurally reduces realized revenue per unit sold and compresses net product margins. If elevated co‑pay support or 340B utilization persist, this will sustainably lower cash generated from sales and dampen margin leverage from future volume growth.
Clinical And Regulatory Execution RiskA failed subgroup result in STELLAR‑303 raises regulatory and label risk for zanza combinations and could complicate payer coverage and uptake. Combined with 505(b)(2)/ANDA and IP questions, this elevates approval, labeling and adoption uncertainty that may affect commercialization timing and peak penetration.
Exelixis News
0IJO FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest share price was $33.81 and its highest was $57.49 in the past 12 months.
What is Exelixis’s market cap?
Exelixis’s market cap is $12.72B.
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Nov 03, 2026 which is in 82 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on Aug 05, 2026. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.853 by $0.057.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Overvalued.
Does Exelixis pay dividends?
Exelixis pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Exelixis dividends here
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is 0.89.
How many shares outstanding does Exelixis have?
Exelixis has 247,781,700 shares outstanding.
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of $0.91 in its last earnings report, beating expectations of $0.853. Following the earnings report the stock price went down -6.595%.
Which hedge fund is a major shareholder of Exelixis?
Currently, no hedge funds are holding shares in GB:0IJO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Exelixis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$51.75 (-7.79% Downside)
$51.75 (-7.79% Downside)
Blogger Sentiment
Bullish
GB:0IJO Sentiment 82%
Sector Average 61%
Sector Average 61%
Insider Transactions
Sold Shares
Worth $7.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.86%
Trailing 12-Months
Company Description
Exelixis
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
0IJO Company Deck
0IJO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflects strong commercial performance, healthy profitability and a well-advanced zanzalintinib development program with multiple pivotal trials and a pending NDA/PDUFA. These positive fundamentals are tempered by a modestly slower-than-expected NET ramp that prompted a $50 million downward adjustment to revenue guidance, higher gross-to-net expectations (30%–31%), and some clinical/regulatory uncertainties (STELLAR-303 subgroup result, 505(b)(2) dynamics). On balance, the company’s execution, cash position (~$1.4B), active share repurchases, and deep pipeline milestones outweigh the near-term headwinds, supporting a constructive outlook while acknowledging short-term risks.View all GB:0IJO earnings summaries0IJO Revenue Breakdown
89.92% U.S.
7.92% Europe
2.16% Japan
0IJO Stock 12 Month Forecast
Average Price Target
$51.75
▼(-7.79% Downside)